The vascular dementia treatment industry is poised for significant growth, with an estimated market value of USD 5.64 billion in FY 2023, marking a year-on-year increase of over 5%. This surge in demand highlights the growing awareness and need for effective treatments for vascular dementia, a condition that affects millions of individuals worldwide.
Over the forecast period from 2023 to 2033, the market is projected to expand at a robust compound annual growth rate (CAGR) of 4.77%. By FY 2033, the industry is expected to reach a market value of USD 8.99 billion, driven by continued advancements in medical research, increased healthcare access, and an aging global population.
The rise in vascular dementia cases, often linked to conditions such as stroke and cardiovascular disease, is contributing to the growing demand for targeted treatments. As healthcare providers and pharmaceutical companies continue to innovate, the market is anticipated to witness increased investment in both treatment options and early diagnosis technologies.
With the continuous development of new therapies, along with increased healthcare awareness and education, the vascular dementia treatment industry is positioned for sustainable growth, offering hope to those affected by this debilitating condition.
Key Takeaways from the Market Study:
- Market share of individual therapies with the current and forecasted 7 million market size from 2019-2032.
- Decline in thinking skills, caused by conditions that block or reduce blood flow to various brain regions, depriving them of oxygen and nutrients.
- Prevention of treatment aims to reduce the symptoms of the disease by eliminating its cause or main risk factors, with prevention in the management of stroke, by early diagnosis and appropriate treatment of acute stroke
- No cure for the condition or a way to reverse the damage already happened. But treatment can help prevent further damage to the brain in people with vascular dementia and may slow down its progression.
- North America is expected to occupy a major share of the overall dementia drugs market during the forecasted period, followed by Asia where Malaysia has shown that the percentage of the population aged 65 years and over (old age) increased from 6.7% in 2019 to 7.0% in 2020.
“With substance abuse becoming an area of major concern, healthcare providers are looking to collaborate with various entities, including governmental bodies, to push for legalization, as well as develop novel treatment drugs, which will provide ample opportunities for companies to develop key drugs,” remarks an analyst at FMI.
Interest in Market Trends: Get Detailed Analysis and Insights with Our Comprehensive Report!
Competitive Landscape:
The publisher performs competitive and market Intelligence analysis of the Vascular Dementia (VaD) market by using various competitive intelligence tools that include SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
- In April 2022- NovaMedica developed and registered an innovative combination of Donepezil and Memantine molecules, the primary therapies for dementia. The drug is registered under the name MIOREOL. This is one of the combinations in the Russian market and the markets of the Eurasian Economic Union members and Europe.
- In March 2022- Corium, Inc. received United States FDA approval for ADLARITY (donepezil transdermal system) as a treatment for patients with mild, moderate, or severe dementia.
More Valuable Insights Available:
Future Market Insights offers an unbiased analysis of the vascular dementia treatment industry, providing historical data for 2018-2022 and forecast statistics from 2023-2033.
Some of the prominent players are:
- Charsire Biotechnology Corp
- ProNeurogen Therapeutics
- Resverlogix Corp.
- Eisai Co., Ltd.
- Novartis AG
- Cipla Inc.
- Aurobindo Pharma
- Sun Pharmaceutical Industries Ltd
- Dr. Reddy’s Laboratories Ltd
- Johnson & Johnson Services, Inc.
Key Segments Profiled in the Vascular Dementia Treatment Industry Analysis:
By Type:
- Pipeline Development Activities
- Reimbursement Scenario in Vascular Dementia (VaD)
- Multi-infarct dementia
- Binswanger disease
- Vascular dementia from a strategic single-infarct
- BAC: Charsire Biotechnology Corp
- PNA1: ProNeurogen Therapeutics
By Treatment:
- Drug class
- Route of administration
- Distribution channel
By End User:
- Hospitals and Clinics
- Rehabilitation Centers
- Others
By Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East & Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
